FDA postpones plan for new hearing aid sales channel – again

In the US, the option to buy over-the-counter hearing aids has had multiple delays, and from the look of things now, the guidelines for the so-called OTC sales won't be nade public until early 2023 – if then.

Photo: Andrew Kelly/Reuters/Ritzau Scanpix

The farce surrounding the development of a US over-the-counter (OTC) category for the sales of low-cost hearing aids continues.

For some years, hearing aid manufacturers of all sizes and shapes have been waiting with anticipation for the US Food and Drug authority (FDA) to provide the guidelines which will define the contours of how OTC sales of hearing aids will operate in the future.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Further reading

Related articles

Latest news

See all jobs